Login to Your Account

Taiwan's Senhwa tackles cholangiocarcinoma, gets orphan status from FDA

By Christopher Horton
Contributing Writer

Friday, February 3, 2017

TAIPEI, Taiwan – Calling its recent FDA orphan designation for small-molecule drug CX-4945 in cholangiocarcinoma an important milestone, 2012 startup Senhwa Biosciences Inc. enters 2017 with plans for an uplisting on the Taiwan stock exchange.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription